in pictures and a few words
What it is and why it matters
Tapinarof is a steroid-free cream for psoriasis and atopic dermatitis (eczema). It is applied to the skin once a day.
- It is not a steroid ointment
- It does not thin the skin
- It can be used for a long time — on the face and in skin folds too
Why “steroid-free” matters so much
A steroid ointment helps quickly, but with long use it thins the skin. That is why doctors set limits: “two weeks, no longer”, “not on the face”.
- Yet psoriasis and eczema are long-term — treatment goes on for years
- Tapinarof does not thin the skin
- So it has no limits on how long, how much skin or where it is used
How it works
Skin cells contain a “sensor” that tunes the skin’s defences and inflammation. In psoriasis and eczema this tuning is off. The cream gives the skin back its own normal way of working.
- The skin makes more of the proteins that hold its protective layer together
- Inflammation calms down, but the skin’s defences are not switched off entirely
- The molecule was found in nature — in bacteria that live alongside tiny worms
In psoriasis
In adults with psoriasis, skin became clear or almost clear noticeably more often with this cream than with the same cream without the medicine.
- Over almost a year of treatment, many people’s skin became completely clear
- It can be used where a steroid ointment can’t: the face, skin folds
Tested in people. Tested on people: in large studies in adults with psoriasis.
In atopic dermatitis
In adults and children from age two, skin became clear or almost clear more often with the cream than with the same cream without the medicine. Itching eased quickly.
- Atopic dermatitis is eczema
- Over almost a year, most people’s skin was clear or almost clear at least once
- In children it most often affects the face, neck and folds — the cream can go there
Tested in people. Tested on people: in adults and in children from age two.
After stopping — months of calm
When the skin became completely clear, the cream was stopped and people were simply watched. On average, months passed before the rash came back.
- In psoriasis this break was longer than in eczema
- That is rare for a cream: usually the disease returns within weeks of stopping
How to apply it
The cream is applied once a day. It is used not all the time but until the skin is clear; then there is a break, and if the rash comes back, treatment starts again.
- It can go on the face, neck and in skin folds
- For psoriasis — adults from 18
- For atopic dermatitis — from age two
What may appear
Most often — folliculitis: small inflamed bumps at the roots of hairs, usually on covered parts of the body. It is common, so it’s worth knowing about before the first application.
- It is usually mild and rarely makes people stop treatment
- Less often the skin reacts to the cream itself
- Sometimes — headache, a runny nose, a cold
Tested in people. In eczema, people stopped treatment because of side effects even less often than with the same cream without the medicine.
Who should see a doctor first
The cream treats the skin from the outside. Sometimes the cream alone is not enough and treatment that acts on the whole body is needed — a doctor chooses it.
- The rash covers noticeably more than a fifth of the skin
- Psoriasis with painful joints: the cream does not act on joints
- Psoriasis with pus-filled spots or redness over almost all the skin
Important. Prescribing the cream and the treatment schedule are decided by a doctor.
In one sentence
Tapinarof is a steroid-free cream for psoriasis and eczema: it does not thin the skin, it is applied once a day, and it can be used for a long time and on the face. It’s worth knowing about folliculitis in advance.
Key points
Tapinarof (brand name VTAMA) is a 1% steroid-free cream and the first aryl hydrocarbon receptor (AhR) modulator: it is applied once daily, does not cause skin atrophy, and so carries no limits on duration, treated area or body site — the face and folds included.
| Condition | How it helps | What human studies showed |
|---|---|---|
| Plaque psoriasis in adults | repairs the skin barrier and damps interleukin-17, the dominant inflammatory pathway in psoriasis | PSOARING 1 and 2, 1,025 adults, 12 weeks: clear or almost clear skin in 35.4% and 40.2% versus 6.0% and 6.3% on vehicle cream [1]; PSOARING 3, 40 weeks: completely clear skin in 40.9%; in those who reached it, lesions took a mean of 130 days to return after stopping [2] |
| Moderate-to-severe atopic dermatitis in adults and children from age 2 | upregulates the barrier proteins filaggrin and loricrin and damps interleukins 4 and 13 | ADORING 1 and 2, 813 patients, 8 weeks: response in 45.4% and 46.4% versus 13.9% and 18.0%, itch improved rapidly [3]; ADORING 3, 48 weeks: completely clear skin in 51.9%; in those who reached it, the first treatment-free interval averaged 79.8 days [4] |
How it helps
A steroid ointment works quickly and predictably. The problem is not efficacy — it is the built-in counter: prolonged use thins the skin, leaves striae and visible vessels, and on the face readily produces perioral dermatitis.
So the physician always draws a line: two weeks, no longer; not on the face; not over a large area. Yet psoriasis and atopic dermatitis are chronic, and treatment runs for years. That gap produced both patient steroid phobia and the biggest unfilled niche in dermatology: a non-steroidal topical that can be used for a long time and everywhere.
How it works
Tapinarof is a synthetic analogue of a stilbene produced by bacteria of the genus Photorhabdus, which live in symbiosis with nematodes. The molecule was not designed at a chemist's bench — it was found in natural material and developed into a drug.
Its target is the aryl hydrocarbon receptor (AhR), a sensor inside the cell. It evolved to read chemical signals from the environment: tryptophan breakdown products, compounds from plant food, metabolites of the skin microbiome. Through it the skin tunes two things at once — barrier strength and the level of inflammation. In psoriasis and eczema that tuning is off.
A steroid ointment acts like the main light switch: it shuts inflammation down wholesale, useful activity included. And the longer you keep it off, the more the room itself fades — that fading is skin atrophy.
Tapinarof is not a switch but a dial that restores the skin's own factory programme. By activating AhR it upregulates the barrier proteins filaggrin and loricrin — precisely the ones genetically in short supply in atopic dermatitis — while damping the inflammatory signal: interleukin-17 in psoriasis, interleukins 4 and 13 in eczema. An antioxidant response is switched on alongside.
Hence the logic of two indications at once: the barrier is repaired in both diseases, and the inflammatory pathway that dominates each one is the one turned down.
| Tapinarof | Topical steroids | Calcineurin inhibitors | PDE-4 inhibitors | |
|---|---|---|---|---|
| Steroid | No | Yes | No | No |
| Skin atrophy with long-term use | No | Yes | No | No |
| Duration limit | None | Yes | None | None |
| Face and folds | Permitted | Restricted | Permitted | Permitted |
| Burning on application | Uncommon | No | Common early on | Sometimes |
| Applications per day | Once | One to two | Twice | One to two |
| Indications | Psoriasis and atopic dermatitis | Both | Mainly atopic dermatitis | Mainly atopic dermatitis |
In psoriasis
PSOARING 1 and 2 (NEJM, 2021) are two identical phase 3 trials in adults with mild-to-severe plaque psoriasis affecting 3–20% of body surface. The primary endpoint was clear or almost clear skin with at least a 2-grade improvement at week 12 [1]. In PSOARING 3 (JAAD, 2022) — 40 weeks of open-label continuation, 763 patients — 58.2% of those who entered the extension with plaques still visible (mild to severe) reached clear or almost clear skin [2].
The most interesting number is about carry-over. Patients who reached completely clear skin were taken off treatment and simply observed: the mean interval with no therapy at all before lesions returned was 130 days — close to four months. For a topical agent that is atypical: disease usually returns within weeks of stopping.
In atopic dermatitis
ADORING 1 and 2 (JAAD, 2024) are two phase 3 trials. Response was assessed on the vIGA-AD scale (clear or almost clear skin with at least a 2-grade improvement); a 75% or greater improvement in EASI was reached by 55.8% and 59.1% versus 22.9% and 21.2% [3]. In ADORING 3 (JAAD, 2025) — 48 weeks, 728 patients — 81.6% reached clear or almost clear skin at least once [4].
Where it sits in treatment
| Situation | Treatment |
|---|---|
| Psoriasis up to 20% of skin, mild to severe | Topical steroids, vitamin D analogues, tapinarof |
| Extensive psoriasis (more than 20% of skin) | Phototherapy, methotrexate, apremilast, deucravacitinib, biologics |
| Mild atopic dermatitis | Emollients, short steroid courses, calcineurin inhibitors |
| Moderate-to-severe atopic dermatitis | Emollients, short steroid courses, calcineurin inhibitors, tapinarof; if topical treatment is not enough — dupilumab and other systemic agents |
The niche for tapinarof is long-term topical treatment without steroids — where a steroid can no longer be used because the limit is spent, or could never be used because the site is the face, a fold, or a child.
How to use it
| Parameter | Detail |
|---|---|
| Formulation | 1% cream |
| Frequency | Once daily |
| Treated area | No formal limit |
| Body sites | Face, neck and folds included |
| Duration | No limit |
| Age | Psoriasis from 18, atopic dermatitis from 2 |
The pattern is not continuous application but intermittent: treat to clear skin → stop → observe → restart if lesions return. That is exactly how the long-term trials were built, and it is the schedule on which the off-therapy remission figures were obtained.
Who should see a doctor first
- Patients with substantially more than 20% of body surface involved: the issue is not safety but that topical therapy stops being practical.
- Psoriatic arthritis, pustular and erythrodermic psoriasis — systemic therapy is required: a topical agent has no effect on joints.
- Contact dermatitis — 5.5% in psoriasis.
- Headache, nasopharyngitis, upper respiratory infections — within a few percent each.
In the atopic dermatitis trials, discontinuations due to adverse events were fewer on tapinarof than in the group receiving vehicle cream.
Bottom line
Tapinarof repairs the skin barrier and damps inflammation at the same time without causing atrophy — so it can be used for a long time, over any area and on the face. Two indications: plaque psoriasis in adults and atopic dermatitis from age 2; in those who reached completely clear skin, lesions took a mean of 130 days to return after stopping in psoriasis and 80 in eczema.
Treatment can be discussed at a consultation; the drug can be ordered here.
References
1. Lebwohl MG, et al. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. N Engl J Med. 2021;385(24):2219–2229. PMID 34879448
2. Strober B, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial. J Am Acad Dermatol. 2022;87(4):800–806. PMID 35772599
3. Silverberg JI, et al. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol. 2024;91(3):457–465. PMID 38777187
4. Bissonnette R, et al. Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial. J Am Acad Dermatol. 2025;93(3):707–714. PMID 40383273
5. VTAMA (tapinarof) — US Prescribing Information, Organon.
Caveats
- No head-to-head data against potent steroid ointments or systemic drugs such as dupilumab: comparison with vehicle cream proves the molecule works but does not support any claim of being stronger or weaker.
- Remission after stopping — these are means from open-label trials with no control group; the authors note the figure may be underestimated by the study design. No individual can be promised four months of remission.
- Little data beyond a year: the longest trials run 48 weeks in eczema and one year in psoriasis.
- Treated area. The psoriasis trials studied 3–20% of body surface involvement; evidence outside that range is thin.
- Not studied below age 2.
- Long-range safety of sustained AhR activation — a receptor through which dioxins also act — has been measured over years, not decades. No warning signals appeared in the trials, but those are two different statements.
For information only. Prescribing and the treatment schedule are decided by a doctor.
Key facts
- Tapinarof (brand name VTAMA, Dermavant/Organon) is a 1% cream applied once daily and the first member of a new class: aryl hydrocarbon receptor (AhR) modulating agents. The FDA approved it in May 2022 for plaque psoriasis in adults and in December 2024 for atopic dermatitis in adults and children down to 2 years of age.
- It is neither a corticosteroid nor a calcineurin inhibitor: it does not cause skin atrophy, so it carries no limit on treated area, duration of use, or body site — the face and skin folds included. Activating AhR upregulates the barrier proteins filaggrin and loricrin while downregulating interleukin-17 in psoriasis and Th2 cytokines (interleukins 4 and 13) in eczema.
- Psoriasis: in PSOARING 1 and 2 (NEJM, 2021), clear or almost clear skin with at least a 2-grade improvement at week 12 was reached by 35.4% and 40.2% of patients versus 6.0% and 6.3% on vehicle cream; in PSOARING 3 (JAAD, 2022), 40.9% reached completely clear skin over 40 weeks, and in those who reached completely clear skin, lesions took a mean of 130 days to return after stopping — close to four months.
- Atopic dermatitis: in ADORING 1 and 2 (JAAD, 2024), across 813 patients including children from age 2, the week-8 response was reached by 45.4% and 46.4% versus 13.9% and 18.0% on vehicle; in ADORING 3 (JAAD, 2025), 51.9% reached completely clear skin over 48 weeks, and the mean first treatment-free interval after clearance was 79.8 days.
- The dosing pattern is intermittent: treat to clear skin, then stop and watch, and restart if lesions return. The most frequent adverse event is folliculitis (22.7% over a year in psoriasis and 12.1% in atopic dermatitis), usually mild; patients are warned about it in advance.
